Compare UCL & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCL | INCR |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 79.3M |
| IPO Year | 2020 | N/A |
| Metric | UCL | INCR |
|---|---|---|
| Price | $1.70 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.7K | ★ 148.6K |
| Earning Date | 11-12-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.06 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $85,239,000.00 | $72,158,312.00 |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | $20.86 | $41.75 |
| P/E Ratio | $13.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $0.68 |
| 52 Week High | $4.19 | $1.79 |
| Indicator | UCL | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 26.20 |
| Support Level | $1.95 | $1.02 |
| Resistance Level | $2.25 | $1.51 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 11.54 | 2.09 |
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.